drugset / Trial / NCT05156281

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

NCT05156281

Phase 3 Active not recruiting 1007 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)

Timeline

Start
2021-12-13
Primary completion
2026-07-23
Completion
2030-10-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Remibrutinib Small molecule Oral
Comparator Teriflunomide Small molecule Oral

Indications